TechLab, Inc.

TechLab, Inc. , based in the US, specializes in developing diagnostic products that identify infectious diseases, providing essential tools for healthcare providers and laboratories worldwide. Founded in 1989, TechLab, Inc. focuses on creating diagnostic products aimed at identifying infectious diseases.

The company is currently headquartered in the US. TechLab was acquired by SSI Diagnostica A/S in August 2022 from Pharos Capital Group, a transaction that supported the acquirer's expansion into diagnostic test services. TechLab, Inc. specializes in developing and manufacturing diagnostic products aimed at identifying infectious diseases.

Its core offerings include the C. DIFF QUIK CHEK COMPLETE® test, which detects both GDH antigen and toxins A & B in a single, multi-step test, providing results in just ten minutes. Another significant product is the LEUKO EZ VUE® test, designed to detect elevated levels of fecal lactoferrin, a marker for intestinal inflammation. These diagnostic tools primarily serve healthcare providers, laboratories, and research institutions globally, facilitating the rapid identification of conditions such as C.

difficile infections and other gastrointestinal disorders. TechLab, Inc. generates revenue through the sale of its diagnostic products, including the C. DIFF QUIK CHEK COMPLETE® and LEUKO EZ VUE® tests.

The company operates primarily on a B2B model, supplying its products to healthcare facilities, laboratories, and academic institutions. Transactions typically involve direct sales agreements where clients purchase diagnostic kits in bulk for patient testing. By establishing partnerships with distributors and engaging in contract manufacturing services, TechLab enhances its market presence. Following its acquisition on August 22, 2022, TechLab, Inc.

is set to utilize the synergies from SSI Diagnostica A/S to enhance its diagnostic test services. The acquisition positions the company to further expand into new markets, particularly in North America, Europe, and Asia, where there is growing demand for efficient diagnostic solutions. The focus will be on launching new products designed to improve diagnostic capabilities, although specific product release dates have not been disclosed.